Trials / Completed
CompletedNCT00602342
Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions
A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 250 mg Terbinafine Hydrochloride Tablets Under Fasting Conditions
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Roxane Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Terbinafine |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2004-04-01
- Completion
- 2004-04-01
- First posted
- 2008-01-28
- Last updated
- 2018-01-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00602342. Inclusion in this directory is not an endorsement.